The only reason I won't put EXEL on my "Next Killer Stock" list (which currently comprises 6 stocks) is because the company is still in developmental stage and is unprofitable, but it has huge future potential.
Here is a video testimonial of drug XL184, Exelixis' main drug.
Here is a video testimonial of drug XL184, Exelixis' main drug.
No comments:
Post a Comment